Abstract
Cytokinins are phytohormones critically involved in the regulation of plant growth and development. They also affect the proliferation and differentiation of animal cells, thus representing new tools to treat diseases that involve dysfunctional cell growth and/or differentiation. Recently, by performing structure-function studies on human cells, we found that only N6-isopentenyladenosine and its benzyl analogue N6-benzyladenosine suppress the clonogenic activity and the growth of different neoplastic cells. We here broaden our studies on bladder carcinoma T24 cells, because, due to the high recurrence rate of bladder cancer, new active molecules are sought to contrast the growth of this tumor. Early events induced by N6-isopentenyladenosine and N6-benzyladenosine are the alteration of T24 cell morphology and the disorganization of the actin cytoskeleton. After 24 h N6-isopentenyladenosine and N6-benzyladenosine inhibit growth by arresting the cells in the G0/G1 phase of the cell cycle. We also show that the two compounds induce apoptosis, an event linked to the activation of caspase 3. Since DNA damage is a prime factor resulting in cell cycle arrest and apoptosis, it is noteworthy that we do not detect any genotoxic effect upon treatment of T24 cells with N6-isopentenyladenosine and N6- benzyladenosine.
Because the disruption of actin filaments leads to G1 arrest and is also implicated in apoptosis, we hypothesize that cytoskeletal rearrangement might be responsible for triggering the antiproliferative and proapotpotic effects of N6-isopentenyladenosine and N6- benzyladenosine in T24 cells.Keywords: Actin, Apoptosis, Bladder carcinoma cells, Caspase 3, Cell cycle, Cell density, Comet assay, Cytokinin, Cytoskeleton, Cytotoxicity, Genotoxicity, N6-benzyladenine, N6-benzyladenosine, N6-isopentenyladenosine
Anti-Cancer Agents in Medicinal Chemistry
Title:N6-Isopentenyladenosine and its Analogue N6-Benzyladenosine Induce Cell Cycle Arrest and Apoptosis in Bladder Carcinoma T24 Cells
Volume: 13 Issue: 4
Author(s): Sara Castiglioni, Silvana Casati, Roberta Ottria, Pierangela Ciuffreda and Jeanette A.M. Maier
Affiliation:
Keywords: Actin, Apoptosis, Bladder carcinoma cells, Caspase 3, Cell cycle, Cell density, Comet assay, Cytokinin, Cytoskeleton, Cytotoxicity, Genotoxicity, N6-benzyladenine, N6-benzyladenosine, N6-isopentenyladenosine
Abstract: Cytokinins are phytohormones critically involved in the regulation of plant growth and development. They also affect the proliferation and differentiation of animal cells, thus representing new tools to treat diseases that involve dysfunctional cell growth and/or differentiation. Recently, by performing structure-function studies on human cells, we found that only N6-isopentenyladenosine and its benzyl analogue N6-benzyladenosine suppress the clonogenic activity and the growth of different neoplastic cells. We here broaden our studies on bladder carcinoma T24 cells, because, due to the high recurrence rate of bladder cancer, new active molecules are sought to contrast the growth of this tumor. Early events induced by N6-isopentenyladenosine and N6-benzyladenosine are the alteration of T24 cell morphology and the disorganization of the actin cytoskeleton. After 24 h N6-isopentenyladenosine and N6-benzyladenosine inhibit growth by arresting the cells in the G0/G1 phase of the cell cycle. We also show that the two compounds induce apoptosis, an event linked to the activation of caspase 3. Since DNA damage is a prime factor resulting in cell cycle arrest and apoptosis, it is noteworthy that we do not detect any genotoxic effect upon treatment of T24 cells with N6-isopentenyladenosine and N6- benzyladenosine.
Because the disruption of actin filaments leads to G1 arrest and is also implicated in apoptosis, we hypothesize that cytoskeletal rearrangement might be responsible for triggering the antiproliferative and proapotpotic effects of N6-isopentenyladenosine and N6- benzyladenosine in T24 cells.Export Options
About this article
Cite this article as:
Castiglioni Sara, Casati Silvana, Ottria Roberta, Ciuffreda Pierangela and A.M. Maier Jeanette, N6-Isopentenyladenosine and its Analogue N6-Benzyladenosine Induce Cell Cycle Arrest and Apoptosis in Bladder Carcinoma T24 Cells, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (4) . https://dx.doi.org/10.2174/1871520611313040016
DOI https://dx.doi.org/10.2174/1871520611313040016 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ruthenium Complexes as Anticancer Agents
Current Medicinal Chemistry Signal Transduction Therapy Targeting Apoptosis Pathways in Cancers
Current Signal Transduction Therapy Bladder Cancer Stem Cells: Biological and Therapeutic Perspectives
Current Stem Cell Research & Therapy Nanomedicines for Intravesical Chemotherapy in Bladder Cancer
Current Pharmaceutical Design The Macrophage Stimulating Protein/Ron Pathway as a Potential Therapeutic Target to Impede Multiple Mechanisms Involved in Breast Cancer Progression
Current Drug Targets Synthesis of Pyrophosphate-Containing Compounds that Stimulate VγVδ2 T Cells: Application to Cancer Immunotherapy
Medicinal Chemistry The Production and Role of Gastrin-17 and Gastrin-17-Gly in Gastrointestinal Cancers
Protein & Peptide Letters Design of Telomerase Inhibitors for the Treatment of Cancer
Current Pharmaceutical Design Nano-engineered Adsorbent for the Removal of Dyes from Water: A Review
Current Analytical Chemistry Drug-Delivery Systems of Green Tea Catechins for Improved Stability and Bioavailability
Current Medicinal Chemistry Dendrimers and Dendritic Polymers as Anti-infective Agents: New Antimicrobial Strategies for Therapeutic Drugs
Anti-Infective Agents in Medicinal Chemistry Clinical Applications of Positron Emission Tomography (PET) Imaging in Medicine: Oncology, Brain Diseases and Cardiology
Current Radiopharmaceuticals Physcion and Physcion 8-O-β-D-glucopyranoside: Natural Anthraquinones with Potential Anticancer Activities
Current Drug Targets Antisense Oligonucleotides as an Innovative Therapeutic Strategy in the Treatment of High-Grade Gliomas
Recent Patents on CNS Drug Discovery (Discontinued) Circulating microRNAs in Hepatocellular Carcinoma: Potential Diagnostic and Prognostic Biomarkers
Current Pharmaceutical Design Immunomodulation in Inflammatory Neuropathies: Rationale and Safety
Current Drug Safety Possibilities of Poly(D,L-lactide-co-glycolide) in the Formulation of Nanomedicines Against Cancer
Current Drug Targets Arsenic Trioxide Targets miR-125b in Glioma Cells
Current Pharmaceutical Design New Anti-Angiogenic Targeted Therapy in Advanced Renal Cell Carcinoma (RCC):Current Status and Future Prospects
Reviews on Recent Clinical Trials Labelling and Tracking of Human Mesenchymal Stromal Cells in Preclinical Studies and Large Animal Models of Degenerative Diseases
Current Stem Cell Research & Therapy